{
    "2020-01-31": [
        [
            {
                "time": "2018-03-01",
                "original_text": "Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study",
                "features": {
                    "keywords": [
                        "Olumiant",
                        "eczema",
                        "late-stage",
                        "succeeds"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-05",
                "original_text": "Form 8.3 - Abbvie Plc",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "Abbvie"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-15",
                "original_text": "Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat",
                "features": {
                    "keywords": [
                        "Amgen",
                        "stock down",
                        "Q4 earnings",
                        "revenue beat"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Decisions, Decisions: AbbVie or Bristol-Myers Squibb?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Bristol-Myers Squibb",
                        "comparison"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-02-20",
                "original_text": "AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "CHMP",
                        "MAVIRET",
                        "positive opinion",
                        "treatment duration"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "CHMP",
                        "VENCLYXTO",
                        "chemotherapy-free",
                        "chronic lymphocytic leukemia"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}